Who Generates Higher Gross Profit? Teva Pharmaceutical Industries Limited or BioCryst Pharmaceuticals, Inc.

Teva vs. BioCryst: A Decade of Gross Profit Comparison

__timestampBioCryst Pharmaceuticals, Inc.Teva Pharmaceutical Industries Limited
Wednesday, January 1, 20141348600011056000000
Thursday, January 1, 20154636100011356000000
Friday, January 1, 20162365400011859000000
Sunday, January 1, 20172348400010825000000
Monday, January 1, 2018201820008296000000
Tuesday, January 1, 2019447340007536000000
Wednesday, January 1, 2020161360007725000000
Friday, January 1, 20211499060007594000000
Saturday, January 1, 20222642330006973000000
Sunday, January 1, 20233267510007646000000
Monday, January 1, 20248064000000
Loading chart...

Igniting the spark of knowledge

A Tale of Two Pharmaceutical Giants: Teva vs. BioCryst

In the competitive world of pharmaceuticals, gross profit is a key indicator of a company's financial health and market position. Over the past decade, Teva Pharmaceutical Industries Limited has consistently outperformed BioCryst Pharmaceuticals, Inc. in terms of gross profit. From 2014 to 2023, Teva's gross profit averaged around $9 billion annually, peaking in 2016 with a staggering $11.9 billion. In contrast, BioCryst's gross profit, while showing growth, remained significantly lower, with an average of $93 million per year.

Despite Teva's dominance, BioCryst has shown remarkable growth, particularly in recent years. From 2021 to 2023, BioCryst's gross profit surged by over 100%, reaching $327 million in 2023. This growth trajectory suggests a promising future for BioCryst as it continues to innovate and expand its market presence. As the pharmaceutical landscape evolves, these two companies exemplify the dynamic nature of the industry.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025